Huntsman CORP HUN

Healthcare SIC 2800 - Chemicals & Allied Products NAICS Manufacturing › Chemical Manufacturing derived NYSE

We are a global manufacturer of diversified organic chemical products. We operate in three segments: Polyurethanes, Performance Products and Advanced Materials. Our products comprise many different chemicals and chemical formulations, which we market globally to a wide range of consumers that consist primarily of industrial and building product manufacturers. Our products are used in a broad range of applications, including those in the adhesives, aerospace, automotive, coatings and construction, construction products, durable and non-durable consumer products, electronics, insulation, power generation and refining. Many of our products offer effects such as premium insulation in homes and buildings and the lightweighting of airplanes and automobiles that help conserve energy. We are a leading global producer in many of our key product lines, including MDI, amines, maleic anhydride and epoxy-based polymer formulations. Our revenues for the years ended December 31, 2025, 2024 and 2023 were $5,683 million, $6,036 million and $6,111 million, respectively.

Last close 8.80 2026-10-23
Market cap $1.54B 2026-03-31 share count
52-week range 7.29 - 16.09

Valuation FY2025 figures against the last close

P/S0.3x
P/E—
P/FCF13.3x
EV/EBITDA20.0x
Dividend yield9.5%
Diluted EPS-1.65

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $5.68B$6.04B$6.11B$8.02B$7.67B$5.42B$6.80B$7.60B$6.84B$7.52B
Cost of revenue $4.93B$5.17B$5.21B$6.48B$6.09B$4.44B$5.42B$5.84B$5.19B$6.00B
Gross profit $751.0M$866.0M$906.0M$1.55B$1.58B$977.0M$1.38B$1.76B$1.65B$1.52B
R&D $120.0M$121.0M$115.0M$125.0M$135.0M$121.0M$137.0M$145.0M$132.0M$137.0M
SG&A $670.0M$671.0M$689.0M$711.0M$739.0M$670.0M$786.0M$789.0M$759.0M$772.0M
Total operating expenses $882.0M$891.0M$822.0M$874.0M$853.0M$545.0M$913.0M$937.0M$922.0M$855.0M
Operating income -$131.0M-$25.0M$84.0M$672.0M$731.0M$432.0M$469.0M$827.0M$729.0M$663.0M
Interest expense —————————$202.0M
Pre-tax income -$192.0M-$39.0M$99.0M$697.0M$1.25B$331.0M$391.0M$734.0M$531.0M$474.0M
Income tax $26.0M$61.0M$64.0M$186.0M$191.0M$42.0M$38.0M$45.0M$20.0M$109.0M
Net income -$284.0M-$189.0M$101.0M$460.0M$1.04B$1.03B$562.0M$337.0M$636.0M$326.0M
EPS, basic -1.65-1.100.572.294.774.692.461.422.671.38
EPS, diluted -1.65-1.100.572.274.724.662.441.392.611.36
Shares, diluted (wtd. avg.) 172.6M172.1M177.4M203.0M221.4M221.9M230.6M241.6M243.9M239.6M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $429.0M$340.0M$540.0M$654.0M$1.04B$1.59B$525.0M$340.0M$481.0M$396.0M
Inventory $818.0M$917.0M$867.0M$995.0M$1.04B$848.0M$914.0M$1.00B$1.07B$918.0M
Total current assets $2.06B$2.12B$2.31B$3.15B$3.93B$3.57B$3.75B$2.96B$5.98B$3.56B
Property, plant and equipment $2.49B$2.49B$2.38B$2.38B$2.44B$2.50B$2.38B$2.35B$3.10B$3.03B
Goodwill $630.0M$633.0M$644.0M$641.0M$650.0M$533.0M$276.0M$275.0M$140.0M$121.0M
Other intangibles $308.0M$344.0M$387.0M$425.0M$469.0M$453.0M$197.0M$213.0M$56.0M$43.0M
Total assets $7.01B$7.11B$7.25B$8.22B$9.39B$8.71B$8.32B$7.95B$10.24B$9.19B
Accounts payable ———$907.0M$1.05B$842.0M$765.0M$761.0M$946.0M$774.0M
Short-term debt $353.0M$325.0M$12.0M$66.0M$12.0M$593.0M$212.0M$96.0M$40.0M$50.0M
Total current liabilities $1.59B$1.56B$1.17B$1.70B$2.05B$1.98B$2.01B$1.61B$3.27B$1.78B
Long-term debt $1.66B$1.51B$1.68B$1.67B$1.54B$1.53B$2.18B$2.22B$2.26B$4.12B
Total liabilities $4.06B$3.95B$3.77B$4.38B$4.83B$5.04B$5.50B$5.20B$6.87B$7.72B
Retained earnings $1.81B$2.25B$2.62B$2.71B$2.44B$1.56B$690.0M$292.0M$161.0M-$325.0M
Total equity $2.75B$2.96B$3.48B$3.84B$4.56B$3.67B$2.82B$2.75B$3.37B$1.47B

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $289.0M$263.0M$209.0M$914.0M$952.0M$253.0M$897.0M$1.21B$1.22B$1.09B
Depreciation and amortisation $287.0M$289.0M$278.0M$281.0M$278.0M$267.0M$270.0M$255.0M$236.0M$318.0M
Stock-based compensation $31.0M$30.0M$28.0M$29.0M$30.0M$26.0M$29.0M$27.0M$36.0M$32.0M
Capital expenditure $173.0M$184.0M$230.0M$272.0M$326.0M$237.0M$274.0M$251.0M$234.0M$318.0M
Investing cash flow -$132.0M-$126.0M$305.0M-$279.0M-$524.0M$1.46B-$260.0M-$973.0M-$424.0M-$203.0M
Financing cash flow -$76.0M-$326.0M-$620.0M-$994.0M-$977.0M-$655.0M-$450.0M-$424.0M-$519.0M-$723.0M
Dividends paid $146.0M$174.0M$169.0M$171.0M$159.0M$144.0M$150.0M$156.0M$120.0M$120.0M
Buybacks $0$4.0M$349.0M$1.00B$200.0M$96.0M$208.0M$277.0M——

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001437749-26-004524.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -2.5B 0 2.5B 5B 7.5B 10B Revenue, FY2016: 7.5B Gross profit, FY2016: 1.5B Net income, FY2016: 326M Revenue, FY2017: 6.8B Gross profit, FY2017: 1.7B Net income, FY2017: 636M Revenue, FY2018: 7.6B Gross profit, FY2018: 1.8B Net income, FY2018: 337M Revenue, FY2019: 6.8B Gross profit, FY2019: 1.4B Net income, FY2019: 562M Revenue, FY2020: 5.4B Gross profit, FY2020: 977M Net income, FY2020: 1B Revenue, FY2021: 7.7B Gross profit, FY2021: 1.6B Net income, FY2021: 1B Revenue, FY2022: 8B Gross profit, FY2022: 1.5B Net income, FY2022: 460M Revenue, FY2023: 6.1B Gross profit, FY2023: 906M Net income, FY2023: 101M Revenue, FY2024: 6B Gross profit, FY2024: 866M Net income, FY2024: -189M Revenue, FY2025: 5.7B Gross profit, FY2025: 751M Net income, FY2025: -284M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $7.52B $6.84B $7.60B $6.80B $5.42B $7.67B $8.02B $6.11B $6.04B $5.68B
Gross profit $1.52B $1.65B $1.76B $1.38B $977.0M $1.58B $1.55B $906.0M $866.0M $751.0M
Net income $326.0M $636.0M $337.0M $562.0M $1.03B $1.04B $460.0M $101.0M -$189.0M -$284.0M

Recent filings and events

  • Shareholder vote The results of the annual meeting or a special vote. Item 5.07
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • Regulation FD disclosure Item 7.01
  • Other event Item 8.01
  • Shareholder vote Item 5.07
  • Results announced Item 2.02
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Results announced Item 2.02
  • Material agreement signed Item 1.01

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 2800

TickerCompanyMarket capP/ERevenue growth
SOLS Solstice Advanced Materials Inc. $9.44B 39.9x 3.1%
BCPC BALCHEM CORP $5.64B 37.3x 8.8%
PRM Perimeter Solutions, Inc. $4.55B — 16.4%
IOSP INNOSPEC INC. $2.43B 21.1x -3.7%
NGVT Ingevity Corp $2.39B — -2.7%
CC Chemours Co $1.93B — 0.4%
OLN OLIN Corp $1.78B — 3.7%
ECVT Ecovyst Inc. $1.07B — 20.9%